GlassScriptPhysician profile
Terri Wallace
NPI 1356796262
$1,871.05
in general payments reported to CMS, 2019-2025
15 companies · $80.48 in 2025
The $80.48 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $315 · 2023: $793 · 2024: $566 · 2025: $80.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.31 | 2021-2024 | Wegovy |
| Servier Pharmaceuticals LLC | $128.96 | 2023 | |
| Viiv Healthcare Company | $124.73 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $122.10 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.09 | 2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $116.55 | 2023 | Austedo |
| Neurocrine Biosciences, INC. | $113.35 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $112.77 | 2023 | Gvoke Hypopen |
| Sk Life Science, INC. | $107.93 | 2023 | Xcopri |
| Lilly USA, LLC | $100.54 | 2024 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.24 | 2022 | |
| Alkermes, INC. | $24.40 | 2025 | Aristada, Lybalvi |
| Abbvie INC. | $20.61 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.04 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $17.43 | 2025 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.